GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Median PS Value

Amryt Pharma (Amryt Pharma) Median PS Value : $0.00 (As of Jun. 10, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Amryt Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $3.697. Amryt Pharma's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-06-10), Amryt Pharma's share price is $14.70. Amryt Pharma's Median PS Value is $0.00. Therefore, Amryt Pharma's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Amryt Pharma's Median PS Value or its related term are showing as below:

AMYT's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.81
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Amryt Pharma Median PS Value Historical Data

The historical data trend for Amryt Pharma's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Median PS Value Chart

Amryt Pharma Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amryt Pharma Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Amryt Pharma's Median PS Value

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amryt Pharma's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Price-to-Median-PS-Value falls into.



Amryt Pharma Median PS Value Calculation

Amryt Pharma's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=3.697*0
=0.00

10-Year Median PS Ratio is 0.
Amryt Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.697.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amryt Pharma  (NAS:AMYT) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Amryt Pharma's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=14.70/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amryt Pharma Median PS Value Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Amryt Pharma (Amryt Pharma) Business Description

Traded in Other Exchanges
N/A
Address
196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).